Boxer Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Boxer Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,590,000	Closed	-$18.4M	–	25
2024 Q3	$18.4M	Hold	1,590,000	–	–	0.9%	29
2024 Q2	$18.7M	Hold	1,590,000	–	–	0.99%	28
2024 Q1	$18.9M	Sell	1,590,000 -60,000	-4%	-$800K	0.93%	32
2023 Q4	$20.2M	Hold	1,650,000	–	–	1.01%	26
2023 Q3	$15.9M	Hold	1,650,000	–	–	0.85%	36
2023 Q2	$14.8M	Hold	1,650,000	–	–	0.69%	39
2023 Q1	$13M	Buy	+1,650,000	New	+$12.3M	0.64%	41
2020 Q1	–	Sell	-200,000	Closed	-$3.56M	–	65
2019 Q4	$3.56M	Hold	200,000	–	–	0.2%	47
2019 Q3	$2.32M	Hold	200,000	–	–	0.17%	46
2019 Q2	$4.43M	Hold	200,000	–	–	0.38%	33
2019 Q1	$5.72M	Hold	200,000	–	–	0.66%	21
2018 Q4	$3.95M	Hold	200,000	–	–	0.49%	21
2018 Q3	$4.42M	Buy	+200,000	New	+$2.7M	0.49%	18

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Boxer Capital's KALV Position: Q4 2024 in Review

Boxer Capital sold out of KalVista Pharmaceuticals (KALV) in Q4 2024, closing a stake of 1,590,000 shares — an estimated $18.4M sold.

Boxer Capital first reported a position in KALV in Q3 2018 and held it in 13 quarters. The position peaked at $20.2M in Q4 2023. 130 funds tracked by Wall St. Rank hold KALV as of Q4 2024.

Boxer Capital reported no remaining KalVista Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 1,590,000 KalVista Pharmaceuticals shares in Q4 2024, an estimated $18.4M.
Boxer Capital first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 13 quarters.
Boxer Capital's KalVista Pharmaceuticals position peaked at $20.2M in Q4 2023.
130 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.